Application of Compressed Sensing 3D MR cholangiopancreatography (CS-MRCP) with Contact-Free Physiological Monitoring (CFPM) for Pancreaticobiliary Disorders.

RATIONAL AND

OBJECTIVES

To prospectively evaluate the clinical feasibility of the magnetic resonance cholangiopancreatography (MRCP) protocol using both contact-free physiological monitoring (CFPM) and compressed sensing (CS) (CS-CFPM-MRCP) and to compare its performance with that of the standard navigator-triggered (NT) CS-NT-MRCP and NT-MRCP.

MATERIALS AND

METHODS

A total of 63 patients (36 males, 27 females, age range: 18-83 years, mean age: 52.30 ± 15.70 years) suspected with duct-related pathologies were prospectively enrolled and performed the three MRCP protocols randomly. The acquisition time was compared. The pancreaticobiliary system was divided into 12 segments and evaluated based on a five-point Likert scale and compared by the Friedman test with a post hoc test. The diagnostic performance of the 3 MRCP was evaluated by the AUC value and compared by Delong's test. The interobserver agreement was evaluated by Kendall's W test.

RESULTS

Compared to NT-MRCP, the acquisition time of CS-NT-MRCP and CS-CFPM-MRCP was significantly decreased (both p < 0.001). There is no significant difference in the overall imaging quality (p > 0.05) between the NT-MRCP and CS-CFPM-MRCP protocols. CS-CFPM-MRCP depicted pancreatic duct and intrahepatic ducts better than CS-NT-MRCP (all p < 0.05) and was comparable with that of the NT-MRCP (all p > 0.05). For identification of abnormalities and diseases associated with MPD anatomy, the mean AUC value for NT-MRCP and CS-CFPM-MRCP were 0.896 (95%CI: 0.834, 0.958) and 0.905 (95%CI: 0.846, 0.964), which were significantly higher when compared to that for CS-NT-MRCP (0.713 [95%CI:0.622, 0.805]) (p = 0.001 and < 0.001). All evaluations showed good to excellent agreement (0.619-0.897).

CONCLUSION

The combination of CS and CFPM is considered feasible for shortening the scan time of 3D free breath MRCP without impairing the imaging quality and CS-CFPM-MRCP is considered feasible for patients suspected with pancreaticobiliary diseases.